Literature DB >> 3711340

Circulating immune complexes and immunoglobulin A rheumatoid factor in patients with mesangial immunoglobulin A nephropathies.

C Czerkinsky, W J Koopman, S Jackson, J E Collins, S S Crago, R E Schrohenloher, B A Julian, J H Galla, J Mestecky.   

Abstract

Circulating immune complexes (CIC) containing IgA and C3 were elevated in 48% of IgA nephropathy patients; IgA1 was the predominant subclass. IgA1-IgG CIC were detected in 44%, IgA2-IgG CIC in 7%, and IgM-IgA1 CIC in 16% of the patients. No IgM-IgA2 CIC were detectable. Sucrose gradient ultracentrifugation indicated that IgG-IgA1 CIC were predominantly of intermediate (13-19S) size whereas IgA1-C3 CIC sedimented from 11S to 19S. At acid pH, isolated CIC revealed the presence of substantial amounts of 7S IgA. One third of the patients had elevated serum IgA rheumatoid factor (RF) of both polymeric and monomeric forms despite normal levels of IgM-RF; 87% of patients with elevated IgA-RF had IgA1-IgG CIC. These results indicate that the IgA1 component of CIC in patients with IgA nephropathy is not necessarily of mucosal origin and suggest that a portion of these CIC consists of IgA RF immunologically complexed with autologous IgG.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 3711340      PMCID: PMC370554          DOI: 10.1172/JCI112522

Source DB:  PubMed          Journal:  J Clin Invest        ISSN: 0021-9738            Impact factor:   14.808


  61 in total

1.  Recurrence of mesangial deposition of IgA after renal transplantation.

Authors:  J Berger; H Yaneva; B Nabarra; C Barbanel
Journal:  Kidney Int       Date:  1975-04       Impact factor: 10.612

2.  IgA-deposits in cutaneous blood-vessel walls and mesangium in Henoch-Schönlein syndrome.

Authors:  E H Faille-Kuyber; L Kater; C J Kooiker; E J Dorhout Mees
Journal:  Lancet       Date:  1973-04-21       Impact factor: 79.321

3.  [Intercapillary deposits of IgA-IgG].

Authors:  J Berger; N Hinglais
Journal:  J Urol Nephrol (Paris)       Date:  1968-09

4.  The interactions of human complement with interfacially aggregated preparations of human secretory IgA.

Authors:  R J Boackle; K M Pruitt; J Mestecky
Journal:  Immunochemistry       Date:  1974-09

5.  Immune complex type glomerulonephritis in cirrhosis of the liver.

Authors:  P Callard; G Feldmann; D Prandi; M F Belair; C Mandet; Y Weiss; P Druet; J P Benhamou; J Bariety
Journal:  Am J Pathol       Date:  1975-08       Impact factor: 4.307

6.  Detection of circulating antigen-antibody complexes by their inhibitory effect on the agglutination of IgG-coated particles by rheumatioid factor of Clq.

Authors:  A Z Lurhuma; C L Cambiaso; P L Masson; J F Heremans
Journal:  Clin Exp Immunol       Date:  1976-08       Impact factor: 4.330

7.  The secretory immune system and renal disease.

Authors:  R S Dobrin; F E Knudson; A F Michael
Journal:  Clin Exp Immunol       Date:  1975-08       Impact factor: 4.330

8.  IgA and glomerular disease.

Authors:  J A Whitworth; S Leibowitz; M C Kennedy; J S Cameron; C Chantler
Journal:  Clin Nephrol       Date:  1976-01       Impact factor: 0.975

9.  Circulating immune complexes in the serum in systemic lupus erythematosus and in carriers of hepatitis B antigen. Quantitation by binding to radiolabeled C1q.

Authors:  U E Nydegger; P H Lambert; H Gerber; P A Miescher
Journal:  J Clin Invest       Date:  1974-08       Impact factor: 14.808

10.  Lack of IgA subclass restriction in antibody response to phosphorylcholine, beta lactoglobulin and tetanus toxoid.

Authors:  M E Conley; D E Briles
Journal:  Immunology       Date:  1984-11       Impact factor: 7.397

View more
  71 in total

Review 1.  Progress in molecular and genetic studies of IgA nephropathy.

Authors:  J Novak; B A Julian; M Tomana; J Mesteck
Journal:  J Clin Immunol       Date:  2001-09       Impact factor: 8.317

2.  IgA1 is the major immunoglobulin component of immune complexes in the acquired immune deficiency syndrome.

Authors:  S Jackson; L M Dawson; D P Kotler
Journal:  J Clin Immunol       Date:  1988-01       Impact factor: 8.317

3.  IgA-containing immune complexes after challenge with food antigens in patients with IgA nephropathy.

Authors:  S Jackson; Z Moldoveanu; K A Kirk; B A Julian; T F Patterson; A L Mullins; T Jilling; J Mestecky; J H Galla
Journal:  Clin Exp Immunol       Date:  1992-08       Impact factor: 4.330

4.  Increased and prolonged production of specific polymeric IgA after systemic immunization with tetanus toxoid in IgA nephropathy.

Authors:  L Layward; A C Allen; S J Harper; J M Hattersley; J Feehally
Journal:  Clin Exp Immunol       Date:  1992-06       Impact factor: 4.330

Review 5.  Biomarkers in IgA nephropathy: relationship to pathogenetic hits.

Authors:  Margaret Colleen Hastings; Zina Moldoveanu; Hitoshi Suzuki; Francois Berthoux; Bruce A Julian; John T Sanders; Matthew B Renfrow; Jan Novak; Robert J Wyatt
Journal:  Expert Opin Med Diagn       Date:  2013-11

6.  Detection and characterization of circulating and glomerular immune complexes in experimental IgA nephropathy.

Authors:  J González-Cabrero; J Egido; A Barat; E González
Journal:  Immunology       Date:  1990-07       Impact factor: 7.397

7.  Anti-IgA antibodies in IgA-deficient children.

Authors:  F H Sennhauser; C S Hosking; C L Jones; R A MacDonald; N Mermelstein; D M Roberton
Journal:  J Clin Immunol       Date:  1988-09       Impact factor: 8.317

8.  IgA and IgG immune complexes increase human macrophage C3 biosynthesis.

Authors:  J Laufer; H Boichis; N Farzam; J H Passwell
Journal:  Immunology       Date:  1995-02       Impact factor: 7.397

9.  Characterization of circulating idiotypes containing immune complexes and their presence in the glomerular mesangium in patients with IgA nephropathy.

Authors:  J González-Cabrero; J Egido; F Mampaso; M C Rivas; L Hernando
Journal:  Clin Exp Immunol       Date:  1989-05       Impact factor: 4.330

10.  Mesangial cell autoantigens in immunoglobulin A nephropathy and Henoch-Schönlein purpura.

Authors:  D J O'Donoghue; A Darvill; F W Ballardie
Journal:  J Clin Invest       Date:  1991-11       Impact factor: 14.808

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.